ASND Ascendis Pharma A/S Stock Quote

ASND [NASD]

Index	-	P/E	-	EPS (ttm)	-9.79	Insider Own	0.03%	Shs Outstand	53.76M	Perf Week	-0.08%
Market Cap	6.90B	Forward P/E	-	EPS next Y	-7.36	Insider Trans	0.00%	Shs Float	43.77M	Perf Month	-4.90%
Income	-509.20M	PEG	-	EPS next Q	-2.14	Inst Own	-	Short Float	6.83%	Perf Quarter	-12.73%
Sales	6.70M	P/S	1030.14	EPS this Y	-76.60%	Inst Trans	0.98%	Short Ratio	13.29	Perf Half Y	-25.06%
Book/sh	18.17	P/B	7.17	EPS next Y	7.30%	ROA	-47.10%	Target Price	194.79	Perf Year	-7.77%
Cash/sh	15.27	P/C	8.53	EPS next 5Y	24.00%	ROE	-54.50%	52W Range	119.11 - 183.98	Perf YTD	-21.90%
Dividend	-	P/FCF	-	EPS past 5Y	-43.00%	ROI	-35.50%	52W High	-26.32%	Beta	0.75
Dividend %	-	Quick Ratio	9.40	Sales past 5Y	-3.10%	Gross Margin	-	52W Low	13.80%	ATR	5.89
Employees	482	Current Ratio	9.40	Sales Q/Q	-68.20%	Oper. Margin	-	RSI (14)	54.48	Volatility	3.09% 4.65%
Optionable	Yes	Debt/Eq	0.12	EPS Q/Q	11.50%	Profit Margin	-	Rel Volume	1.53	Prev Close	130.25
Shortable	Yes	LT Debt/Eq	0.11	Earnings	May 27 AMC	Payout	-	Avg Volume	224.98K	Price	135.55
Recom	1.60	SMA20	1.83%	SMA50	2.55%	SMA200	-9.90%	Volume	200,250	Change	4.07%

Mar-30-21

Downgrade

Oppenheimer

Outperform → Perform

Mar-11-21

Resumed

Stifel

Buy

$190

Dec-17-20

Initiated

Berenberg

Buy

$216

Sep-14-20

Resumed

JP Morgan

Overweight

$160

Mar-20-20

Initiated

Oppenheimer

Outperform

$199

Oct-11-19

Initiated

Morgan Stanley

Overweight

$128

Mar-25-19

Initiated

Evercore ISI

Outperform

Jan-24-19

Upgrade

Leerink Partners

Mkt Perform → Outperform

Jan-24-19

Initiated

Cantor Fitzgerald

Overweight

$102

Jun-26-18

Initiated

Stifel

Buy

$85

Apr-02-18

Reiterated

Leerink Partners

Mkt Perform

$37 → $64

May-11-17

Initiated

JP Morgan

Overweight

$36

Mar-09-17

Downgrade

Leerink Partners

Outperform → Mkt Perform

Feb-09-17

Initiated

Credit Suisse

Outperform

$28

Sep-26-16

Initiated

Wedbush

Outperform

$34

Jun-14-21 10:41AM	Ascendis' (ASND) BLA for GHD Candidate Gets Review Extension Zacks
Jun-11-21 05:57PM	Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon hGH (Lonapegsomatropin) for Pediatric Growth Hormone Deficiency GlobeNewswire
Jun-03-21 01:59PM	The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial PR Newswire
May-28-21 01:00PM	Ascendis Pharma A/S (ASND) Q1 2021 Earnings Call Transcript Motley Fool
07:05AM	Ascendis Pharma A/S Invites the Public to Attend A Story of Courage: Living with Hypoparathyroidism in Support of World Hypopara Awareness Day on June 1, 2021 GlobeNewswire
May-27-21 04:01PM	Ascendis Pharma A/S Reports First Quarter 2021 Financial Results GlobeNewswire
May-17-21 04:05PM	Ascendis Pharma A/S Announces First Quarter 2021 Financial Results and Business Update Conference Call on May 27 GlobeNewswire
May-14-21 01:38AM	We're Not Very Worried About Ascendis Pharma's (NASDAQ:ASND) Cash Burn Rate Simply Wall St.
May-12-21 04:28PM	Ascendis Pharma A/S Announces Expansion of Global Clinical Reach for TransCon PTH with Filing of the Clinical Trial Notification for Phase 3 Clinical Trial in Adults with Hypoparathyroidism in Japan GlobeNewswire
May-11-21 08:17AM	Ascendis Pharma's TransCon PTH Provides Durable Benefit, Is Well Tolerated Even After One Year Treatment In Hypoparathyroidism Benzinga
May-10-21 05:17PM	Ascendis Pharma A/S Announces Preliminary 58-Week Results from Open-Label Extension of Phase 2 PaTH Forward Trial of TransCon PTH in Adult Hypoparathyroidism Demonstrated Durable Benefit and a Well-Tolerated Safety Profile GlobeNewswire
May-06-21 04:05PM	Ascendis Pharma A/S Announces Presentations for TransCon PTH at Upcoming Medical Conferences GlobeNewswire
01:10PM	Should You Consider Investing in Ascendis Pharma (ASND)? Insider Monkey
May-04-21 04:05PM	Ascendis Pharma A/S Announces Participation at the BofA Securities 2021 Virtual Health Care Conference GlobeNewswire
Apr-21-21 04:05PM	Ascendis Pharma A/S Announces Presentations for TransCon hGH at Upcoming Medical Conferences GlobeNewswire
Apr-19-21 03:19PM	Is ASND Stock A Buy or Sell? Insider Monkey
Apr-07-21 09:45PM	Analysts Say These 3 Stocks Are Their Top Picks for 2021 TipRanks
Mar-30-21 07:05AM	Ascendis Pharma A/S Announces Participation at the J.P. Morgan 10th Annual Napa Valley Biotech Forum GlobeNewswire
Mar-23-21 07:05AM	Ascendis Pharma A/S Presents 6-Month Open-Label Extension Data from Phase 2 PaTH Forward Trial of TransCon PTH in Adult Hypoparathyroidism at ENDO 2021 GlobeNewswire
Mar-15-21 07:05AM	Ascendis Pharma A/S Announces Participation at Oppenheimer 31st Annual Healthcare Conference GlobeNewswire
Mar-11-21 05:30AM	Ascendis Pharma A/S (ASND) Q4 2020 Earnings Call Transcript Motley Fool
Mar-10-21 04:01PM	Ascendis Pharma A/S Reports Full Year 2020 Financial Results GlobeNewswire
07:05AM	Ascendis Pharma A/S Announces Seven Presentations at ENDO 2021, Demonstrating Commitment to People with Rare Endocrine Diseases GlobeNewswire
Mar-09-21 10:16AM	Earnings Preview for Ascendis Pharma Benzinga
Mar-04-21 04:05PM	Ascendis Pharma A/S Announces Full Year 2020 Financial Results and Business Update Conference Call on March 10 GlobeNewswire -6.18%
Feb-26-21 07:05AM	Ascendis Pharma A/S Announces New Outgrow GHD Educational Resource to Support Rare Disease Day 2021 GlobeNewswire
Feb-18-21 04:05PM	Ascendis Pharma A/S Announces Participation at SVB Leerink 10th Annual Global Healthcare Conference GlobeNewswire -5.77%
Jan-14-21 08:29AM	New Strong Sell Stocks for January 14th Zacks
Jan-13-21 11:02AM	New Strong Sell Stocks for January 13th Zacks
Jan-10-21 07:04PM	Ascendis Pharma A/S Provides Vision 3x3 Update at 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-08-21 10:06PM	VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China PR Newswire
07:39PM	Ascendis Pharma A/S Announces Equity Investment in VISEN Pharmaceuticals GlobeNewswire
Jan-04-21 07:05AM	Ascendis Pharma A/S Announces Participation in 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-30-20 04:05PM	Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon TLR7/8 Agonist Clinical Program GlobeNewswire
08:47AM	Implied Volatility Surging for Ascendis Pharma (ASND) Stock Options Zacks
Dec-14-20 04:05PM	Ascendis Pharma A/S Announces Planned Board Transition GlobeNewswire
Nov-25-20 07:05AM	Ascendis Pharma A/S Announces Participation at the Evercore ISI 3rd Annual HealthCONx Virtual Conference GlobeNewswire
Nov-15-20 07:20AM	Earnings Update: Ascendis Pharma A/S (NASDAQ:ASND) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts Simply Wall St.
Nov-11-20 05:30PM	Ascendis Pharma A/S to Host Virtual Oncology R&D Day on Friday, November 20 GlobeNewswire
04:24PM	Recap: Ascendis Pharma Q3 Earnings Benzinga
04:01PM	Ascendis Pharma A/S Reports Third Quarter 2020 Financial Results GlobeNewswire
07:38AM	The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap Benzinga
Nov-10-20 08:40AM	Why Earnings Season Could Be Great for Ascendis (ASND) Zacks
Nov-04-20 10:12AM	Sorrento (SRNE) to Report Q3 Earnings: What's in the Cards? Zacks +5.01%
10:09AM	Catalyst (CPRX) to Report Q3 Earnings: What's in the Cards? Zacks
Nov-03-20 07:05AM	Ascendis Pharma A/S Appoints Dr. Mark A. Bach as Senior Vice President of Clinical Development and Medical Affairs for Endocrinology Rare Diseases GlobeNewswire
Nov-02-20 04:05PM	Ascendis Pharma A/S Announces Third Quarter 2020 Financial Results and Business Update Conference Call on November 11 GlobeNewswire
Oct-23-20 08:05AM	Ascendis Pharma A/S Receives Orphan Designation for TransCon PTH for Treatment of Hypoparathyroidism in Europe GlobeNewswire
Oct-21-20 05:51PM	Ascendis Pharma A/S Announces Presentations for its Endocrinology Rare Disease Clinical Programs at Upcoming Medical Conferences GlobeNewswire
Oct-08-20 06:40PM	Free Stock Pick From Insider Monkeys Monthly Newsletter Insider Monkey
Sep-29-20 11:04AM	Ascendis Progresses With Hypoparathyroidism Drug TransCon PTH Zacks
Sep-28-20 07:00PM	Ascendis Pharma A/S Announces Preliminary Six-Month Data from Open-Label Extension of Phase 2 PaTH Forward Trial and Files IND Amendment to Initiate Phase 3 PaTHway Trial of TransCon PTH in Adult Hypoparathyroidism GlobeNewswire
Sep-23-20 04:05PM	Ascendis Pharma A/S Announces Filing of the Clinical Trial Notification for Phase 3 Clinical Trial of TransCon hGH for Pediatric Growth Hormone Deficiency in Japan GlobeNewswire
Sep-15-20 05:45PM	Ascendis Pharma A/S Announces Support for Childrens Growth Awareness Week and Day 2020 GlobeNewswire
08:30AM	Is Ascendis Pharma A/S (ASND) Going to Burn These Hedge Funds? Insider Monkey
Sep-11-20 07:05AM	Ascendis Pharma A/S Announces Participation at the 18th Annual Morgan Stanley Virtual Global Healthcare Conference GlobeNewswire
Sep-10-20 07:05AM	Ascendis Pharma A/S Announces Presentations for TransCon PTH and Hypoparathyroidism at American Society for Bone and Mineral Research Annual Meeting GlobeNewswire
Sep-08-20 04:44PM	Ascendis Pharma A/S Submits Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TransCon hGH for Treatment of Pediatric Growth Hormone Deficiency GlobeNewswire
Sep-04-20 08:30AM	Ascendis Pharma A/S Announces U.S. Food and Drug Administration (FDA) Accepts Biologics License Application (BLA) for TransCon hGH for Pediatric Growth Hormone Deficiency (GHD) GlobeNewswire
07:05AM	Ascendis Pharma A/S Announces Presentations for TransCon PTH and Hypoparathyroidism at 22nd European Congress of Endocrinology GlobeNewswire
Sep-02-20 04:05PM	Ascendis Pharma A/S Announces Participation at the 2020 Wells Fargo Virtual Healthcare Conference GlobeNewswire
Aug-27-20 10:00PM	Ascendis Pharma A/S (ASND) Q2 2020 Earnings Call Transcript Motley Fool
04:24PM	Ascendis Pharma: Q2 Earnings Insights Benzinga
04:01PM	Ascendis Pharma A/S Reports Second Quarter 2020 Financial Results and Announces New Data from the Four-Week, Fixed Dose, Double-Blind Portion of the PaTH Forward Trial GlobeNewswire
Aug-21-20 09:48AM	The Ascendis Pharma (NASDAQ:ASND) Share Price Is Up 646% And Shareholders Are Delighted Simply Wall St.
Aug-13-20 04:01PM	Ascendis Pharma A/S Announces Second Quarter 2020 Financial Results and Business Update Conference Call on August 27 GlobeNewswire
12:48PM	Ascendis' Dwarfism Candidate Gets Orphan Drug Status in EU Zacks
Aug-12-20 07:05AM	Ascendis Pharma A/S Receives Orphan Designation for TransCon CNP for the Treatment of Achondroplasia in Europe GlobeNewswire
Aug-04-20 08:30AM	Ascendis Pharma A/S Announces Upcoming Investor Presentations in August GlobeNewswire
Jul-24-20 09:47AM	Why Ascendis Pharma (ASND) Stock is a Compelling Investment Case Insider Monkey
Jul-10-20 08:49PM	Did Hedge Funds Make The Right Call On Ascendis Pharma A/S (ASND) ? Insider Monkey
Jul-07-20 10:11PM	Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs GlobeNewswire
Jul-06-20 12:58PM	Ascendis Pharma A/S Announces Proposed Public Offering of ADSs GlobeNewswire
09:25AM	Ascendis Pharma A/S Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan GlobeNewswire
Jun-29-20 11:44AM	Ascendis Submits BLA to FDA for TransConhGH in Pediatric GHD Zacks
Jun-26-20 08:29AM	Ascendis Pharma A/S Announces Submission of Biologics License Application (BLA) to FDA for TransCon hGH in Pediatric Growth Hormone Deficiency GlobeNewswire
Jun-22-20 08:30AM	Ascendis Pharma A/S Announces Presentation of Preclinical Data for TransCon IL-2 / at AACR Virtual Annual Meeting 2020 GlobeNewswire
Jun-10-20 12:27PM	Ascendis Pharma Clears Technical Benchmark, Hitting 80-Plus RS Rating Investor's Business Daily
Jun-08-20 08:15AM	Ascendis Pharma A/S Announces Participation in ENDO Online 2020 GlobeNewswire
Jun-03-20 03:46PM	Should You Avoid Ascendis Pharma A/S (ASND)? Insider Monkey
May-29-20 09:28PM	Merit Medical Reaches Deal With Starboard Value Barrons.com
May-22-20 06:14AM	Earnings Beat: Ascendis Pharma A/S (NASDAQ:ASND) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts Simply Wall St.
May-19-20 04:01PM	Ascendis Pharma A/S Reports First Quarter 2020 Financial Results GlobeNewswire
02:30PM	Ascendis Pharma A/S to Host Earnings Call ACCESSWIRE
May-11-20 08:30AM	Ascendis Pharma A/S Will Appoint Jesper Høiland as Global Chief Commercial Officer GlobeNewswire
May-08-20 11:46AM	7 Strong Buy Healthcare Stocks to Buy Now InvestorPlace
May-07-20 04:01PM	Ascendis Pharma A/S Announces First Quarter 2020 Financial Results and Business Update Conference Call on May 19 GlobeNewswire
Apr-21-20 06:01AM	Ascendis Pharma A/S (NASDAQ:ASND) Analysts Just Slashed This Year's Revenue Estimates By 12% Simply Wall St. -5.84%
Apr-19-20 04:00PM	Ascendis Pharma A/S Announces Top-line Data from Fixed Dose Portion of Phase 2 Trial Demonstrating Potential of TransCon PTH as a Replacement Therapy for Hypoparathyroidism GlobeNewswire
Apr-16-20 09:40PM	Edited Transcript of ASND earnings conference call or presentation 1-Apr-20 8:30pm GMT Thomson Reuters StreetEvents
Apr-15-20 04:58PM	Ascendis Pharma A/S Receives Orphan Drug Designation for TransCon hGH as Treatment for Growth Hormone Deficiency in the United States GlobeNewswire
Apr-01-20 04:01PM	Ascendis Pharma A/S Reports Full-Year 2019 Financial Results GlobeNewswire
Mar-25-20 04:01PM	Ascendis Pharma A/S Announces Full Year 2019 Financial Results and Business Update Conference Call on April 1 GlobeNewswire
Mar-22-20 08:25PM	Hedge Funds Have Never Been This Bullish On Ascendis Pharma A/S (ASND) Insider Monkey
Mar-21-20 08:49AM	We're Hopeful That Ascendis Pharma (NASDAQ:ASND) Will Use Its Cash Wisely Simply Wall St.
Mar-17-20 12:00PM	Ascendis Pharma A/S (ASND) Moves to Buy: Rationale Behind the Upgrade Zacks
Feb-12-20 04:01PM	Ascendis Pharma A/S Announces Upcoming Investor Presentation in February GlobeNewswire
Feb-10-20 09:28AM	Alkermes (ALKS) to Report Q4 Earnings: What's in Store? Zacks
Feb-06-20 10:44AM	Emmaus (EMMA) to Report Q4 Earnings: What's in the Cards? Zacks
Feb-04-20 11:28AM	Vanguard Health Care Fund Adds 4 Stocks to Portfolio in 4th Quarter GuruFocus.com

Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience